The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. This is the first prospective phase III study ...

Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives Several recent advances have been made ...

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia. Preliminary results from a FIH, open-label phase 1 study with BMC128, a ...

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma. Preliminary activity and ...

Comprehensive genomic profiling of advanced anal adenocarcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text ...

Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials. Comparative risk of obesity-related cancer with glucagon-like ...

Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical ...

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish The following represents disclosure ...

Machine learning for tracking planned versus delivered dose in pancreas SBRT. This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...

Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer.